Mirabegron Glenmark (Mirabegron)

The drug activates β3‑adrenergic receptors in the bladder’s detrusor muscle. This activation relaxes the smooth muscle, allowing the bladder to hold a larger volume of urine and decreasing the frequency of unwanted contractions that cause urgency and leakage.

The appropriate dose is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different class (β3‑adrenergic agonist) and does not have the anticholinergic side‑effects such as dry mouth or constipation that are common with anticholinergic agents. It may be chosen when patients cannot tolerate anticholinergics or when a different mechanism of action is desired.

Store the tablets at ambient temperature below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Mirabegron Glenmark is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include significant hypertension, urinary retention, tachycardia, angioedema and rare cardiac events such as myocardial infarction. Patients should be monitored for these conditions, especially if they have pre‑existing cardiovascular disease.

Mirabegron is contraindicated in patients with uncontrolled hypertension and should be used with caution in those with severe renal or hepatic impairment. Individuals who have experienced severe allergic reactions to mirabegron or any of its excipients should also avoid the medication.